-
Product Insights
Innovations in Metered Dose Inhaler Devices – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Metered Dose Inhaler Devices - Global Pipeline Summary" provides comprehensive information about the Metered Dose Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Metered Dose Inhaler Devices report provides key information and data related to: Extensive coverage of the Metered Dose Inhaler Devices under development Review details of major pipeline products which include product description, licensing and collaboration...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ND-0612 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ND-0612 in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ND-0612 in Parkinson's Disease Drug Details: ND-0612 is under development as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Foscarbidopa + Foslevodopa) in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Foscarbidopa + Foslevodopa) in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Foscarbidopa + Foslevodopa) in Parkinson's Disease Drug Details: Foscarbidopa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Empagliflozin + Metformin) in Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Empagliflozin + Metformin) in Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Empagliflozin + Metformin) in Diabetes Drug Details: The fixed dose...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cilostazol + Rosuvastatin) in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cilostazol + Rosuvastatin) in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cilostazol + Rosuvastatin)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Melphalan in Primary Systemic Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Melphalan in Primary Systemic Amyloidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Melphalan in Primary Systemic Amyloidosis Drug Details: Melphalan (Evomela) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Estradiol + Norethindrone Acetate + Relugolix) in Female Contraception
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Estradiol + Norethindrone Acetate + Relugolix) in Female Contraception report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Estradiol + Norethindrone Acetate + Relugolix)...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Nivolumab + Relatlimab) in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Nivolumab + Relatlimab) in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Nivolumab + Relatlimab) in Gastric Cancer Drug Details: Nivolumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Nivolumab + Relatlimab) in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Nivolumab + Relatlimab) in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Nivolumab + Relatlimab) in Adenocarcinoma Of...